moexiprilat

Moexiprilat是一种血管紧张素转换酶(ACE; IC50 = 2.1 nM)的抑制剂，也是前药moexipril的一种活性代谢产物。通过侧链酯水解作用，在体内从moexipril转化而来。Moexiprilat (10 nM)能防止初生大鼠心脏成纤维细胞在雌激素或血管紧张素II刺激下的增殖。在以每天50 mg/kg剂量给药的去卵巢小鼠中，降低平均动脉血压，并增加心房钠尿肽水平，这是高血压的一个标志。

Moexipril hydrochloride (Moexipril HCl) 是一种有口服活性的，不含巯基的血管紧张素转化酶抑制剂，可治疗高血压和充血性心力衰竭。

Moexipril-d5 intended for use as an internal standard for the quantification of moexipril by GC- or LC-MS. Moexipril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor moexiprilat. It is converted to moexiprilat in vivo by side chain ester hydrolysis. Moexipril inhibits ACE in a cell-free assay (IC50 = 2.7 µM for the rabbit enzyme). It also inhibits phosphodiesterase 4 (IC50s = 38, 160, and 230 µM for PDE4B2, PDE4A5 and PDE4D5, respectively). Moexipril (0.1-30 mg kg per day) reduces blood pressure in spontaneously hypertensive rats.1 It also reduces infarct volume in a rat model of focal cerebral ischemia when used at a concentration of 0.01 mg kg.